The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001243303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
4/09/2026
Date registered
Help: Date registered
13/10/2026
Date last updated
Help: Date last updated
13/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
13/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Phase 1b study evaluating the safety and efficacy of Dendritic cell Immune activation combined with Venetoclax and Azacitidine as frontline therapy for patients with newly diagnosed acute myeloid leukaemia unfit for intensive chemotherapy
Scientific title
Phase 1b study evaluating the safety and efficacy of Dendritic cell Immune activation combined with Venetoclax and Azacitidine as frontline therapy for patients with newly diagnosed acute myeloid leukaemia unfit for intensive chemotherapy
Additional trial identifiers [1] 318355 0
ONJ2025-006
Universal Trial Number (UTN)
Trial acronym
DIVA
Related trial records

Health condition
Health condition(s) studied:
Acute Myeloid Leukaemia 343495 0
Condition category
Condition code
Cancer 339590 339590 0 0
Leukaemia - Acute leukaemia

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
An open-label, single-arm study in which all participants will receive vididencel in combination with standard-of-care venetoclax and azacitidine. The study will evaluate the safety, immunological activity, and clinical activity of vididencel when administered in combination with Ven-Aza in this patient population.
Vididencel (DCP-001) is an off-the-shelf allogeneic dendritic cell (DC) immune activator administered as adjunct immunotherapy in adult patients with newly diagnosed acute myeloid leukaemia (AML) who are measurable residual disease positive (MRD+) and in morphologic complete remission (CR) following frontline venetoclax and azacitidine (Ven-Aza) therapy.
The study consists of 2 phases, in which a total of 24 participants will be enrolled:
• Run-in Phase: To assess the safety of the Vididencel and Ven-Aza combination.
• Expansion Phase: To evaluate the preliminary clinical efficacy of the Vididencel and Ven-Aza combination.

The first 3–6 eligible participants will enter a 28-day run-in phase to determine
safety and tolerability of the novel combination of Vididencel with Ven-Aza.

Once the primary safety endpoint is achieved, these participants will
proceed until the end of study (i.e. 18 months) and for assessment of efficacy and
exploratory outcomes; all subsequent (18–21) participants will be enrolled into the
expansion phase.

Vididencel is administered by intradermal injection by a trained clinician, the Vididencel treatment regimen for all patients enrolled consists of four priming doses followed by two booster doses: The intervention will be administered as inpatient, and administration and visit details will be captured in an electronic database.
Priming Doses (4 doses):
Vididencel 25 × 10^6 cells administered intradermally on: Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 2 Day 15.
Booster Doses (2 doses):
Vididencel 10 × 10^6 cells administered intradermally on: Cycle 4 Day 1 and Cycle 5 Day 1.
Participants will continue to receive standard-of-care venetoclax and azacitidine throughout the study.
Participants will receive 6 cycles of treatment but the vididencel will be only administered according to the previous paragraph. Disease progression, unacceptable toxicity or adverse event are considered sufficient reasons for discontinuing a participant from the trial treatment.
Whilst the study concludes 18 months after enrolment, all participants will be followed for up to 3 years from initial AML diagnosis, or until disease relapse or death, whichever occurs first.
Intervention code [1] 335249 0
Treatment: Drugs
Description of the comparator or control
No control group -
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346771 0
The primary objective of the Run-in phase is to assess safety and tolerability of the Vididencel and Ven-Aza novel combination.
Timepoint [1] 346771 0
Safety assessments will include evaluating adverse events and serious adverse events and concomitant medication/therapies used to treat them for the duration of treatment (6 months) until 28 days after discontinuation of dosing.
Primary outcome [2] 346772 0
The primary objective of the Expansion phase is to evaluate preliminary clinical efficacy of the vididencel and Ven-Aza combination therapy as determined by MRD dynamics.
Timepoint [2] 346772 0
Day 180 post-first dose.
Secondary outcome [1] 467461 0
Response rate
Timepoint [1] 467461 0
Post Study Cycles 1, 2, 5 and at the end of study Day 540 post-first dose.
Secondary outcome [2] 469196 0
Relapse free survival (RFS)
Timepoint [2] 469196 0
Relapse free Survival from Study Day 1 (post-first dose) until end of study Day 540 post-first dose.
Secondary outcome [3] 469197 0
Overall survival (OS)
Timepoint [3] 469197 0
Overall Survival (OS) from date of AML diagnosis until end of study Day 540 post-first dose or death
Secondary outcome [4] 469198 0
Quality of Life (QoL)
Timepoint [4] 469198 0
Patient reported quality of life: EORTC QLQ-C30 on days of investigational product administration (i.e. Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 4 Day 1 & Cycle 5 Day 1)

Eligibility
Key inclusion criteria
A participants will be eligible for trial participation if they meet the following criteria:
1. Adults greater than or equal to 18 years who can provide written informed consent, understand and adhere to study procedures

2. New diagnosis of acute myeloid leukaemia, unfit for intensive chemotherapy and receiving Ven-Aza as frontline induction therapy
a. Prior chemo- or radiotherapy is permitted
b. Prior diagnosis of another myeloid malignancy (e.g. myelodysplastic syndrome, myeloproliferative neoplasm) is permitted

3. Achievement of complete response (CR) as defined by less than 5% bone marrow (BM) blasts after no more than 120 days of Ven-Aza therapy with or without complete haematologic recovery (CRh); PB cell count criteria for CRh defined as:
a. Neutrophil count greater than or equal to 0.5 x10^9/L without Granulocyte Colony-Stimulating Factor (G-CSF) support for 7 days, and
b. Platelet count greater than or equal to 50 x10^9/L without platelet transfusion support for 7 days

4. MRD assessable by MFC and positive by MFC at a level of greater than or equal to 10^–3 at the time of enrolment

5. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0–3

6. Participants must have adequate organ function per laboratory reference range at screening as follows:
a. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5x upper limit normal (ULN).
b. Bilirubin less than or equal to 1.5× ULN in the absence of Gilbert syndrome.
c. Creatinine clearance or glomerular filtration rate greater than or equal to 30 mL/min as estimated by the Cockcroft-Gault or other medically acceptable formulas, such as MDRD (Modification of Diet in Renal Disease) or CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
d. Prothrombin time (PT) and activated partial thromboplastin time (APTT) less than or equal to 1.5x upper limit of normal (ULN); unless patient is receiving anticoagulant therapy and PT or APTT is within or within expected therapeutic range of intended use of anticoagulants

7. Female participants of childbearing potential must have a negative pre-treatment serum pregnancy test at screening

8. Both male and female participants of childbearing potential must agree to use an effective form of contraception such as hormonal birth control, intrauterine device or double barrier method during study treatment period and for at least 180 days after the last dose of the investigational product.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
A participants will not be eligible for trial participation if they meet any of the following criteria:
1. Pregnant or lactating women

2. Vaccine exclusion period — designed to remove vaccination as a confounder for elevation in serum cytokine levels measured as part of DIVA’s correlative studies:
a. Participants must not receive any live attenuated vaccines within 4 weeks prior to the first dose of the investigational product or at any time during the study period.
i. Note: This vaccine exclusion time frame is based on data showing serum immune cytokines returning to pre-vaccination levels 27–32 days after live attenuated small pox vaccine.
b. Inactivated seasonal influenza, COVID-19 mRNA and RSV recombinant vaccines must not be given within 3 weeks prior to the first dose of the investigational product and in the first 8 weeks of the study.
i. Note: The vaccine exclusion time frame prior to study is based on cytokine data of inactivated influenza and COVID-19 vaccines, whereas that post study entry is to remove vaccination as a confounder for elevated serum cytokine levels during at least the priming phase of the investigational product.
c. All other vaccines must not be given within 4 weeks prior to the first dose of the investigational product and in the first 8 weeks of the study. If possible, they should be avoided in the first 6 months of the study.

3. Intent to undergo an allogeneic stem cell transplantation in first CR (CR1)
a. History of allogeneic stem cell transplantation is permitted if the AML is considered therapy-related and not relapsed disease

4. Known or suspected hypersensitivity to Vididencel (or its excipients)

5. History of autoimmune disorders, except for non-severe vitiligo, pernicious anaemia or chronic immune thyroiditis on thyroxine replacement. Additional exclusions should be discussed with the CPI and PI

6. Requirement of ongoing systemic immunosuppressive and corticosteroid therapy
a. A 14-day washout period is required for corticosteroid exposure prednisolone 25mg/day for 3 days or less (or its equivalent)
b. A 28-day washout period is required for corticosteroid exposure of more than prednisolone 25 mg/day for 3 days (or its equivalent)
c. A 6-month washout period is required for other T cell suppressive therapies, including calcineurin inhibitors, mTOR inhibitors, antimetabolites and biologics

7. A second active haematologic or solid organ malignancy
a. A second malignancy demonstrably in remission at the time of enrolment is permitted, provided no treatment was received for that malignancy in the preceding 6 months

8. HIV positive

9. Unstable angina, significant cardiac arrhythmia, or New York Heart Association (NYHA) class 3 or 4 congestive heart failure

10. Evidence of clinically significant infections, including but not limited to:
a. Uncontrolled and/or active systemic infection (viral, bacterial, fungal or parasitic), defined as ongoing symptoms or signs related to the infection without improvement despite appropriate antibiotics or other treatment
b. Chronic hepatitis B (HBV) or hepatitis C virus (HCV) requiring treatment. Note: participants with serologic evidence of prior vaccination to HBV (i.e. surface antigen negative, surface antibody positive and core antibody negative) or positive core antibody from intravenous immunoglobulins (IVIg) may participate

11. Major surgical procedure (including open biopsy) within 28 days prior to the first dose of the investigational product, or planned during the course of the investigational product and 28 days after

12. Any condition or laboratory abnormalities, which places the participant at unacceptable health risk if he/she were to participate in the study

13. Any condition that would impair absorption (i.e. short gut syndrome, malabsorption syndrome)

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 322916 0
Commercial sector/Industry
Name [1] 322916 0
Mendus B.V.
Country [1] 322916 0
Netherlands
Primary sponsor type
Other Collaborative groups
Name
Olivia Newton John Cancer Research Institute (ONJCRI)
Address
Country
Australia
Secondary sponsor category [1] 325849 0
None
Name [1] 325849 0
Address [1] 325849 0
Country [1] 325849 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321342 0
The Royal Melbourne Hospital Human Research Ethics Committee
Ethics committee address [1] 321342 0
Ethics committee country [1] 321342 0
Australia
Date submitted for ethics approval [1] 321342 0
27/05/2026
Approval date [1] 321342 0
31/08/2026
Ethics approval number [1] 321342 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153426 0
Prof Andrew Wei
Address 153426 0
Peter MacCallum Cancer Centre, 305 Grattan Street Melbourne VIC 3000
Country 153426 0
Australia
Phone 153426 0
+61 38559 7469
Fax 153426 0
Email 153426 0
Contact person for public queries
Name 153427 0
Laura Johnston
Address 153427 0
Olivia Newton-John Cancer Research Institute Level 5, ONJ Centre, 145 Studley Road, Heidelberg VIC 3084
Country 153427 0
Australia
Phone 153427 0
+61 39496 9677
Fax 153427 0
Email 153427 0
Contact person for scientific queries
Name 153428 0
Laura Johnston
Address 153428 0
Olivia Newton-John Cancer Research Institute Level 5, ONJ Centre, 145 Studley Road, Heidelberg VIC 3084
Country 153428 0
Australia
Phone 153428 0
+61 39496 9677
Fax 153428 0
Email 153428 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Individual patient data will not be shared publicly. Aggregate patient data and final results will be presented in the final report.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.